SCHEDULE 13D/A: Mount Sinai Entities Divest Significant Stake in GeneDx Holdings, Ceasing 5% Beneficial Ownership

Sentiment:

Schedule 13D Amendment / Exit Filing 21 February 2025 9:30 PM

Icahn School of Medicine at Mount Sinai and Mount Sinai Health System, Inc. have completed sales of GeneDx Holdings Corp. Class A Common Stock, reducing their collective beneficial ownership below 5% and filing their final Schedule 13D amendment.

Worse than expectedThe filing indicates that Icahn School of Medicine at Mount Sinai and Mount Sinai Health System, Inc. have ceased to be beneficial owners of more than five percent of GeneDx Holdings Corp.'s Class A Common Stock.This reduction in ownership below a significant threshold by a major institutional investor is generally perceived as a negative signal for the company's stock.

Summary

This Amendment No. 7 to Schedule 13D serves as the final amendment and exit filing for Icahn School of Medicine at Mount Sinai (ISMMS) and Mount Sinai Health System, Inc. (MSHS) regarding their holdings in GeneDx Holdings Corp. (formerly Sema4 Holdings Corp.).
As of February 21, 2025, ISMMS and MSHS collectively ceased to be beneficial owners of more than five percent of GeneDx's Class A Common Stock.
ISMMS sold 100,000 shares of Class A Common Stock on February 19, 2025, at a price of $108.5723 per share.
ISMMS sold an additional 206,447 shares of Class A Common Stock on February 20, 2025, at a price of $101.0145 per share.
These sales were made in reliance on Rule 144, following a Form 144 filing on January 30, 2025, which disclosed an intention to sell up to 1,346,123 shares within 90 days.
After these dispositions, ISMMS directly owns 1,373,569 shares of Class A Common Stock as of February 24, 2025, representing 4.89% of the class.
All share amounts presented reflect a 33:1 reverse stock split effective May 4, 2023.
The percentage of ownership is based on 28,068,274 shares of Class A Common Stock outstanding as of February 14, 2025, as reported in GeneDx's Annual Report on Form 10-K filed on February 20, 2025.

Sentiment

Score: 3

Explanation: The divestment by a significant institutional holder, reducing their stake below 5%, is generally viewed as a negative signal for the company's stock, implying a lack of long-term conviction or a strategic portfolio shift away from the issuer.

Positives

ISMMS successfully executed sales of a significant portion of its holdings at prices of $108.5723 and $101.0145 per share.

Negatives

Icahn School of Medicine at Mount Sinai and Mount Sinai Health System, Inc. have reduced their beneficial ownership in GeneDx Holdings Corp. below the 5% threshold, indicating a significant divestment by a major institutional holder.

Risks

The reporting persons reserve the right to change their intentions regarding their investment in GeneDx, including potentially disposing of all or a portion of their remaining securities.
The exit of a significant institutional investor could be perceived negatively by the market, potentially impacting investor confidence.

Future Outlook

The reporting persons expect to continuously evaluate GeneDx's financial condition, prospects, and their investment interests. They reserve the right to change their intentions, including increasing or disposing of their remaining holdings in the open market or privately negotiated transactions.

Industry Context

This filing reflects a significant institutional investor, Icahn School of Medicine at Mount Sinai, reducing its stake in a genomics and diagnostic testing company. Such divestments can occur due to portfolio rebalancing, changes in investment strategy, or a reassessment of the company's long-term prospects within the competitive and evolving healthcare technology and diagnostics sector.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Registration Rights	The Subscription Agreements provide for certain customary registration rights for PIPE investors, and the Registration Rights Agreement provides for customary registration rights for certain shareholders.	NA	These agreements facilitate the liquidity of shares for certain investors, including the reporting persons, by allowing them to register and sell their shares.

Stakeholder Impact

Shareholders: The divestment by a significant institutional investor could lead to negative market sentiment and potentially downward pressure on the stock price, as it may be interpreted as a loss of confidence.
Company Management: May need to address investor concerns regarding the institutional exit and articulate their strategy to maintain investor confidence.

Next Steps

This Amendment No. 7 represents the final amendment to the Schedule 13D and constitutes an exit filing for ISMMS and MSHS, indicating they will no longer file Schedule 13D amendments unless their beneficial ownership again exceeds 5%.
The Reporting Persons may continue to evaluate GeneDx's financial condition and prospects and their remaining interests, reserving the right to increase or dispose of their holdings.

Key Dates

Date	Description
October 13, 2021	Initial Schedule 13D filing by Mount Sinai entities.
January 21, 2022	Amendment No. 1 to Schedule 13D filed.
May 6, 2022	Amendment No. 2 to Schedule 13D filed.
February 6, 2023	Amendment No. 3 to Schedule 13D filed.
May 4, 2023	Effective date of the 33:1 reverse stock split of GeneDx's Class A Common Stock.
November 4, 2024	Amendment No. 4 to Schedule 13D filed.
November 15, 2024	Amendment No. 5 to Schedule 13D filed.
January 30, 2025	ISMMS filed Form 144 disclosing intention to sell up to 1,346,123 shares.
February 14, 2025	Date as of which 28,068,274 shares of Class A Common Stock were outstanding, as reported in the Issuer's 10-K.
February 18, 2025	Amendment No. 6 to Schedule 13D filed.
February 19, 2025	ISMMS sold 100,000 shares of Class A Common Stock at $108.5723 per share.
February 20, 2025	ISMMS sold 206,447 shares of Class A Common Stock at $101.0145 per share; GeneDx's Annual Report on Form 10-K filed with the SEC.
February 21, 2025	Date of event requiring this filing, as ISMMS and MSHS ceased to be beneficial owners of more than five percent of Class A Common Stock. This Amendment No. 7 was also filed on this date.
February 24, 2025	Date as of which ISMMS directly owns 1,373,569 shares of Class A Common Stock after the reported dispositions.

Recommendation

sell

Keywords

GeneDx Holdings Corp., Sema4 Holdings Corp., Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, Schedule 13D, Beneficial Ownership, Stock Sale, Divestment, Institutional Investor, Class A Common Stock, Reverse Stock Split, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.